United
States Securities And Exchange Commission
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): January 7,
2011
(December
1, 2010)
|
||
|
||
ISORAY,
INC.
(Exact
name of registrant as specified in its charter)
|
||
Minnesota
(State
or other jurisdiction
of
incorporation)
|
001-33407
(Commission
File
Number)
|
41-1458152
(IRS
Employer
Identification
No.)
|
350 Hills Street, Suite 106,
Richland, Washington 99354
(Address
of principal executive offices) (Zip Code)
(509)
375-1202
(Registrant's
telephone number)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01 Other
Events
On
December 1, 2010, with an effective date of December 1, 2010, IsoRay Medical,
Inc. ("Medical"), a wholly owned subsidiary of IsoRay, Inc. (the "Registrant"),
renewed its Contract (the "Agreement") with UralDial LLC, a Russian company
("UralDial"), dated December 1, 2009. With the renewal of the
Agreement, Medical will continue to purchase Cesium-131 from UralDial and
UralDial will continue to provide Cesium-131 from at least two Russian
facilities subject to scheduled maintenance shutdowns of the facilities from
time to time, through December 31, 2011.
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
Dated: January
6, 2011
IsoRay,
Inc., a Minnesota corporation
|
|||
|
By:
|
Dwight
Babcock
|
|
Dwight
Babcock, CEO
|
|||